Efg Asset Management (North America) Corp. Incyte Corp Transaction History

Efg Asset Management (North America) Corp.

  • $585 Million
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 03, 2023
SELL
$67.18 - $84.11 $112,257 - $140,547
-1,671 Reduced 3.71%
43,353 $3.48 Million
Q3 2022

Oct 28, 2022
SELL
$66.18 - $82.86 $907,658 - $1.14 Million
-13,715 Reduced 23.35%
45,024 $3 Million
Q2 2022

Aug 04, 2022
SELL
$66.18 - $83.18 $501,445 - $630,254
-7,577 Reduced 11.43%
58,739 $4.46 Million
Q1 2022

Apr 26, 2022
SELL
$66.02 - $79.71 $391,630 - $472,839
-5,932 Reduced 8.21%
66,316 $5.27 Million
Q4 2021

Feb 18, 2022
BUY
$63.34 - $74.11 $4.58 Million - $5.35 Million
72,248 New
72,248 $5.31 Million

Others Institutions Holding INCY

# of Institutions
652
Shares Held
186M
Call Options Held
714K
Put Options Held
557K
View Full List

About INCYTE CORP

INCY Quotes by TradingView
  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.1B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email